Approaches to the study of drug-induced liver injury

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 3, 2010, Pages 416-419

  Fontana, R J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BILIRUBIN; COTRIMOXAZOLE; ISONIAZID; NITROFURANTOIN; PHENYTOIN; PROPYLTHIOURACIL; VALPROIC ACID;

DISEASE CLASSIFICATION; DRUG SAFETY; HUMAN; LABORATORY TEST; LIVER TOXICITY; PATHOGENESIS; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; TOXIC HEPATITIS;

BIOMARKERS, PHARMACOLOGICAL; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; HUMANS; INCIDENCE; PHARMACEUTICAL PREPARATIONS; PHENOTYPE; REGISTRIES; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX;

EID: 77955925243     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.100     Document Type: Short Survey

References (22)

1. Temple, R.J. & Himmel, M.H. safety of newly approved drugs: implications for prescribing. JAMA 287, 2273-2275 (2002).
2. Andrade, R.J. et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the spanish registry over a 10-year period. Gastroenterology 129, 512-521 (2005).
3. Galan, M.V., Potts, J.A., Silverman, A.L. & Gordon, S.C. The burden of acute nonfulminant drug-induced hepatitis in a United states tertiary referral center [corrected]. J. Clin. Gastroenterol. 39, 64-67 (2005).
4. Vuppalanchi, R., Liangpunsakul, S. & Chalasani, N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic jaundice in the United states? Am. J. Gastroenterol. 101, 1-5 (2006).
5. Fontana, R.J. Acute liver failure due to drugs. Semin. Liver Dis. 28, 175-187 (2008).
6. Hayashi, P.H. Causality assessment in drug-induced liver injury. Semin. Liver Dis. 29, 348-356 (2009).
7. Papay, J.I. et al. Drug-induced liver injury following positive drug rechallenge. Regul. Toxicol. Pharmacol. 54, 84-90 (2009).
8. Rochon, J. et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 48, 1175-1183 (2008).
9. Bell, L.N. & Chalasani, N. Epidemiology of idiosyncratic drug-induced liver injury. Semin. Liver Dis. 29, 337-347 (2009).
10. Jinjuvadia, K., Kwan, W. & Fontana, R.J. searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am. J. Gastroenterol. 102, 2437-2443 (2007).
11. Meier, Y. et al. Incidence of drug-induced liver injury in medical inpatients. Eur. J. Clin. Pharmacol. 61, 135-143 (2005).
12. Duh, M.S., Walker, A.M. & Kronlund, K.H. Jr. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol. Drug Saf. 8, 275-283 (1999).
13. Sgro, C. et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36, 451-455 (2002).
14. Moore, T.J., Cohen, M.R. & Furberg, C.D. serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch. Intern. Med. 167, 1752-1759 (2007).
15. Us Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry. Drug Induced Liver Injury: premarketing Clinical Evaluation (2009).
16. Fontana, R.J. et al.; DILIN study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 32, 55-68 (2009).
17. Chalasani, N. et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United states. Gastroenterology 135, 1924-1934, 1934.e1 (2008).
18. Ostapowicz, G. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United states. Ann. Intern. Med. 137, 947-954 (2002).
19. Reuben, A., Koch, D.G. & Lee, W.M. Acute liver failure secondary to drug induced liver injury: causes and consequences. (Abstract). Hepatology 54, A #92 (2009).
20. Russo, M.W., Galanko, J.A., Shrestha, R., Fried, M.W. & Watkins, P. Liver transplantation for acute liver failure from drug induced liver injury in the United states. Liver Transpl. 10, 1018-1023 (2004).
21. Daly, A.K. et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to fucloxacillin. Nat. Genet. 41, 816-819 (2009).
22. Fontana, R.J. et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (in press).